In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK, Novartis must divest some assets; Perrigo buys OTC brands; Pfizer buys vaccines

Executive Summary

The European Commission, which ensures that EU law is properly applied, approved GlaxoSmithKline PLC's three transactions in oncology, vaccines, and consumer health with Novartis AG (announced in April 2014), but the approval is subject to certain divestments the companies must make following closing of the deals. Buyers of the assets have not yet been disclosed.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Product Purchase

Related Companies